Our top pick for
Prevail Therapeutics Inc is a biotechnology business based in the US. Prevail Therapeutics shares (PRVL) are listed on the NASDAQ and all prices are listed in US Dollars. Prevail Therapeutics employs 66 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$9.21 - $23.35|
|50-day moving average||$23.03|
|200-day moving average||$13.95|
|Wall St. target price||$23.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.80|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-29.11%|
|Return on equity TTM||-52.34%|
|Market capitalisation||$787.7 million|
TTM: trailing 12 months
There are currently 1.0 million Prevail Therapeutics shares held short by investors – that's known as Prevail Therapeutics's "short interest". This figure is 7.8% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Prevail Therapeutics shares can be evaluated.
Prevail Therapeutics's "short interest ratio" (SIR) is the quantity of Prevail Therapeutics shares currently shorted divided by the average quantity of Prevail Therapeutics shares traded daily (recently around 779390.76923077). Prevail Therapeutics's SIR currently stands at 1.3. In other words for every 100,000 Prevail Therapeutics shares traded daily on the market, roughly 1300 shares are currently held short.
However Prevail Therapeutics's short interest can also be evaluated against the total number of Prevail Therapeutics shares, or, against the total number of tradable Prevail Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prevail Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Prevail Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0615% of the tradable shares (for every 100,000 tradable Prevail Therapeutics shares, roughly 62 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prevail Therapeutics.
Find out more about how you can short Prevail Therapeutics stock.
We're not expecting Prevail Therapeutics to pay a dividend over the next 12 months.
Prevail Therapeutics Inc. , a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.